These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 10744681

  • 1. Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme.
    van der Spoel A, Bonten E, d'Azzo A.
    J Biol Chem; 2000 Apr 07; 275(14):10035-40. PubMed ID: 10744681
    [Abstract] [Full Text] [Related]

  • 2. Early proteolytic cleavage with loss of a C-terminal fragment underlies altered processing of the beta-galactosidase precursor in galactosialidosis.
    Okamura-Oho Y, Zhang S, Hilson W, Hinek A, Callahan JW.
    Biochem J; 1996 Feb 01; 313 ( Pt 3)(Pt 3):787-94. PubMed ID: 8611156
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J, Acosta W, Ayala J, Katta V, Flory A, Martin R, Radin J, Cramer CL, Radin DN.
    Mol Genet Metab; 2016 Feb 01; 117(2):199-209. PubMed ID: 26766614
    [Abstract] [Full Text] [Related]

  • 4. Molecular form and subcellular distribution of acid beta-galactosidase in fibroblasts from patients with GM1 gangliosidosis, Morquio B disease and galactosialidosis.
    Takiyama N, Itoh K, Shimmoto M, Nishimoto J, Inui K, Sakuraba H, Suzuki Y.
    Brain Dev; 1997 Mar 01; 19(2):126-30. PubMed ID: 9105659
    [Abstract] [Full Text] [Related]

  • 5. Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.
    Zhang S, Bagshaw R, Hilson W, Oho Y, Hinek A, Clarke JT, Callahan JW.
    Biochem J; 2000 Jun 15; 348 Pt 3(Pt 3):621-32. PubMed ID: 10839995
    [Abstract] [Full Text] [Related]

  • 6. Characteristics of the beta-galactosidase-carboxypeptidase complex in GM1-gangliosidosis and beta-galactosialidosis fibroblasts.
    D'Agrosa RM, Hubbes M, Zhang S, Shankaran R, Callahan JW.
    Biochem J; 1992 Aug 01; 285 ( Pt 3)(Pt 3):833-8. PubMed ID: 1497621
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.
    Ohto U, Usui K, Ochi T, Yuki K, Satow Y, Shimizu T.
    J Biol Chem; 2012 Jan 13; 287(3):1801-12. PubMed ID: 22128166
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunoelectron microscopical localization of lysosomal beta-galactosidase and its precursor forms in normal and mutant human fibroblasts.
    Willemsen R, Hoogeveen AT, Sips HJ, van Dongen JM, Galjaard H.
    Eur J Cell Biol; 1986 Mar 13; 40(1):9-15. PubMed ID: 3084261
    [Abstract] [Full Text] [Related]

  • 11. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
    Fantur K, Hofer D, Schitter G, Steiner AJ, Pabst BM, Wrodnigg TM, Stütz AE, Paschke E.
    Mol Genet Metab; 2010 Jul 13; 100(3):262-8. PubMed ID: 20409738
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Insights into post-translational processing of beta-galactosidase in an animal model resembling late infantile human G-gangliosidosis.
    Kreutzer R, Kreutzer M, Pröpsting MJ, Sewell AC, Leeb T, Naim HY, Baumgärtner W.
    J Cell Mol Med; 2008 Jul 13; 12(5A):1661-71. PubMed ID: 18088383
    [Abstract] [Full Text] [Related]

  • 14. Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein.
    Callahan JW.
    Biochim Biophys Acta; 1999 Oct 08; 1455(2-3):85-103. PubMed ID: 10571006
    [Abstract] [Full Text] [Related]

  • 15. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
    Luu AR, Wong C, Agrawal V, Wise N, Handyside B, Lo MJ, Pacheco G, Felix JB, Giaramita A, d'Azzo A, Vincelette J, Bullens S, Bunting S, Christianson TM, Hague CM, LeBowitz JH, Yogalingam G.
    J Biol Chem; 2020 Sep 25; 295(39):13556-13569. PubMed ID: 32727849
    [Abstract] [Full Text] [Related]

  • 16. Intracellular processing and maturation of mutant gene products in hereditary beta-galactosidase deficiency (beta-galactosidosis).
    Oshima A, Yoshida K, Itoh K, Kase R, Sakuraba H, Suzuki Y.
    Hum Genet; 1994 Feb 25; 93(2):109-14. PubMed ID: 8112731
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
    Front S, Biela-Banaś A, Burda P, Ballhausen D, Higaki K, Caciotti A, Morrone A, Charollais-Thoenig J, Gallienne E, Demotz S, Martin OR.
    Eur J Med Chem; 2017 Jan 27; 126():160-170. PubMed ID: 27750150
    [Abstract] [Full Text] [Related]

  • 20. Cathepsin A/protective protein: an unusual lysosomal multifunctional protein.
    Hiraiwa M.
    Cell Mol Life Sci; 1999 Dec 27; 56(11-12):894-907. PubMed ID: 11212324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.